Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses
US11292781B2 · kind B2 · utility
2Cited by
46References
40Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 16, 2017 |
| Grant date | Apr 5, 2022 |
| Priority date | — |
| Expiry date | Dec 16, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit RORγ and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.